StockNews.AI
RXST
StockNews.AI
10 hrs

DEADLINE APPROACHING: Berger Montague Advises RxSight, Inc. (NASDAQ: RXST) Investors to Inquire About a Securities Fraud Class Action by September 22, 2025

1. RxSight is under investigation for potential securities fraud claims. 2. The lawsuit alleges undisclosed adoption challenges affecting sales and financial guidance. 3. Defendants reportedly overstated product demand prior to the lawsuit. 4. Investors can seek lead plaintiff status by September 22, 2025. 5. The class period for affected investors spans November 2024 to July 2025.

10m saved
Insight
Article

FAQ

Why Very Bearish?

The allegations of fraud may significantly undermine investor confidence and share value. Historical instances, like the case with Valeant Pharmaceuticals, show how similar allegations led to severe stock declines.

How important is it?

The severity of fraud allegations directly affects RxSight's credibility and stock price; investors are likely to react strongly. Legal actions, especially class actions, have historically triggered significant stock drops.

Why Short Term?

The immediate filing of a class action suggests quick investor reactions and potential market sell-off. Timely actions by other shareholders can exacerbate stock volatility.

Related Companies

VRXENPHPTON

PHILADELPHIA, Sept. 8, 2025 /PRNewswire/ -- Berger Montague PC, a national securities litigation law firm announces it is investigating potential securities fraud claims involving RxSight, Inc. ("RxSight" or the "Company") (NASDAQ:RXST), following the recent filing of a federal securities class action lawsuit.

The lawsuit alleges that Defendants failed to disclose to investors that: (1) RxSight was experiencing "adoption challenges" and/or structural issues resulting in declines in sales and utilization; (2) Defendants had overstated the demand for RxSight's products; and (3) as a result, RxSight was unlikely to meet its own previously issued financial guidance for fiscal year 2025.

Investors who purchased or acquired RxSight securities during the Class Period of November 7, 2024 through July 8, 2025, may, no later than September 22, 2025, seek to be appointed as a lead plaintiff representative of the class.

If you are an RxSight investor and would like to learn more about this action, CLICK HERE or please contact Berger Montague: Andrew Abramowitz at aabramowitz@bergermontague.com or (215) 875-3015, or Caitlin Adorni at cadorni@bergermontague.com or (267)764-4865.

About Berger Montague

Berger Montague is headquartered in Philadelphia and has offices in Chicago; Malvern, PA; Minneapolis; San Diego; San Francisco; Toronto, Canada; Washington, D.C., and Wilmington, DE. The Firm has been a pioneer in securities class action litigation since its founding in 1970. Berger Montague has represented individual and institutional investors for over five decades and serves as lead counsel in courts throughout the United States.

For more information or to discuss your rights, please contact:

Andrew Abramowitz, Senior Counsel

Berger Montague

(215) 875-3015

aabramowitz@bergermontague.com

Caitlin Adorni

Berger Montague

(267) 764-4865

cadorni@bergermontague.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/deadline-approaching-berger-montague-advises-rxsight-inc-nasdaq-rxst-investors-to-inquire-about-a-securities-fraud-class-action-by-september-22-2025-302549750.html

SOURCE Berger Montague

Related News